61 results about "Metabolic intermediate" patented technology

The present invention is directed to compositions that inhibit glycolysis, perferentially in cancer. Specifically, the anticancer compositions comprise 3-halo-2-oxopropionate and its derivatives, such as ester derivatives. However, in specific embodiments, the anticancer composition is sodium 3-halo-2-oxopropionate, such as sodium 3-bromo-2-oxopropionate and a stabilizing agent, such as carbonic acid. In particular embodiments, the compositions of the present invention further comprise a metabolic intermediate for normal cells to utilize in a pathway for an alternate energy source, thereby providing protection to normal cells. In other embodiments, the 3-halo-2-oxopropionate or its ester derivative is used in combination with an additional cancer therapy, such as radiation and/or a drug.

The invention discloses a method for synchronously analyzing a base, a nucleotide, an organic acid, a fatty acid, an amino acid and a saccharide metabolic product with a two-step derivation method. The method comprises the following steps of: performing a series of physicochemical method technical treatment such as ultrasonic treatment, centrifugation, oximation, urea removing, phosphorus removing, sulfur removing, protein removing, nitrogen blowing, vacuum drying, and trimethyl silylation derivation on biological substrate samples (such as urea, blood, cerebrospinal fluid, and tissue fluid); and detecting the biological substrate samples by adopting a gas chromatograph-mass spectrum combination technology. Due to the adoption of method, programmed treatment can be performed on the biological substrate samples simultaneously, and over 400 kinds of metabolic intermediate and final products of over five kinds of substances can be detected at one time.

The invention relates to an integrated style waste gas bio-purifying reactor with two reaction zones, belonging to the equipment utilizing a bioreactor to process the waste gas. A container is divided into a gas humidifying zone, a first biological reaction zone and a second biological reaction zone from bottom to top in sequence by two gas distribution plates. An air inlet and a perforated pipe are arranged on the sidewall of the lower part of the gas humidifying zone, and a drainage outlet is arranged on the sidewall of the upper part. The first biological reaction zone is filled with acid-resistance inert fillers, and the second biological reaction zone is also filled with inert fillers. A spraying liquid inlet and a pipeline connected with a nozzle are arranged on sidewalls of both the first and the second biological reaction zones. An air outlet is also arranged on the sidewall of the second biological reaction zone. Most pollutants in the waste gas are degraded by acidophil bacteria and epiphyte of fillers in the first biological reaction zone. The non-degraded low-concentrated pollutants and metabolic intermediates are fully degraded by heterotrophic bacteria of fillers in the second biological reaction zone. The purified gas is discharged from the air vent.

The invention provides a metabolic transformation strategy for efficiently improving production capacity of corynebacterium crenatum SYPA5-5 L-arginine, and belongs to the biological technical field. Histidine at a site 268 in N-acetyl glutamatekinase, NAGK, argB of SYPA-5 is mutated into asparaginate, so that feedback inhibition effect of the L-arginine on NAGK can be effectively relived; a mutation site is precisely introduced to a corresponding position of SYPA5-5 genome, so that yield of the obtained feedback inhibition-preventing bacterial strain (H-7)L-arginine is lowered, and metabolic intermediate (L-ornithine and L-citrulline) is largely accumulated. Transcriptional analysis is carried out on an arg gene cluster of h-7 to find that arg GH transcriptional level is lowered. Arg GH reinforced expression is carried out in H-7, and production capacity of the obtained recombinant bacterial strain H-7-GH, L-arginine is improved by 99.0% in comparison with SYPA5-5. Preliminary optimization is carried out on a fermentation culture medium of H-7-GH, so that yield of the L-arginine is 45.1g/L, which is improved by 49.8% in comparison with that before optimization, and improved by 1.13 times in comparison with SYPA5-5. Feedback inhibition of the L-arginine on NAGK is relieved, and metabolic transformation strategy of the arg GH gene is expressed in a strengthened manner at the same time, so that production capacity of the L-arginine of the SYPA 5-5 is effectively improved.

The present invention relates to a two-stage process for production of drop-in fuels/alcohols (methanol, ethanol or butanol) from volatile fatty acids produced either synthetically from fossil resources or as metabolic intermediates in acidification step of anaerobic digestion process from waste biomass and organic materials.

It is an objective of the present invention to provide a means of easily mass-producing γ-aminobutyric acid with the use of microorganisms.

The present invention relates to a method for producing a γ-aminobutyric-acid-containing food, comprising causing a yeast or a treated product thereof, which has the ability to produce γ-aminobutyric acid in the presence of a sugar or a metabolic intermediate of sugar metabolism through a fermentation reaction, to act on a sugar, a metabolic intermediate of sugar metabolism, both a sugar or a metabolic intermediate of sugar metabolism and a glutamic acid or a salt thereof.

The invention discloses a tissue culturing method for effectively improving a general flavone content of tartary buckwheat. The tissue culturing method uses a precursor feeding technology. A metabolic intermediate sodium acetate or yeast extract of a flavonoid matter is added in a buckwheat cell suspension culture, so that not only can the general flavone content in the buckwheat culture cell be obviously improved, but also the tissue culturing method has obvious acceleration effect on biomass multiplication of a tissue culture matter. According to the tissue culturing method provided by the invention, the foundation is laid for further developing a buckwheat plant secondary metabolite in a large scale, so that the rapid generation of effective components of the buckwheat plant is achieved; and meanwhile, the tissue culturing method can provide important technical support for further research on molecule conditioning of flavones secondary metabolism in the buckwheat plant.

The present invention provides a prediction method for lipidosis caused by a compound, which comprises detecting (a) phenylacetylglycine and/or phenylacetylglutamine, or an optionally chosen metabolic intermediate in the metabolic pathway from phenylalanine to phenylacetylglycine or phenylacetylglutamine, and (b) hippuric acid or an optionally chosen metabolic intermediate in the metabolic pathway from phenylalanine to hippuric acid, in a sample collected from a mammal receiving the compound or a mammalian cell or tissue culture exposed to the compound, and predicting the compound's potential for inducing lipidosis with the quantitative ratio of the two as the index. The present invention also provides a diagnostic method for lipidosis and diseases related thereto, comprising detecting (a) and (b) above in a sample collected from a mammal, and making a diagnosis with the quantitative ratio of the two as the index.

The invention provides nose washing salt and a preparation method thereof, wherein the nose washing salt provided by the invention is prepared from the following ingredients in parts by weight: 96 to98 parts of refined salt, 0.6 to 1.8 parts of sodium bicarbonate, 0.5 to 2 parts of potassium chloride, 5 to 10 parts of herba rhodiolae and 0.1 to 0.5 part of organosilicon quaternary ammonium salt.The nose washing salt provided by the invention can go deep into the surface skin of the nasal cavity; the nasal cavity secreta can be effectively cleared; scopolamine, kaempferol and the like contained in the herba rhodiolae have the antibacterial and anti-inflammatory effects; tannin contained in the herba rhodiolae can be used for preventing the nasal cavity from secreting excessive dirty materials; the organosilicon quaternary ammonium salt is used as the surfactants; the organic silicon is used as a medium; ammonium cation groups with the sterilization performance are adsorbed onto the surface of staphylococcus aureus; the permeability of the staphylococcus aureus is damaged, so that the enzyme, coenzyme and metabolic intermediates in thalli can overflow; the thalli die through respiratory function asthenia, so that the effect of effectively inhibiting the staphylococcus aureus is achieved.

The invention provides an escherichia coli engineering strain for efficiently producing 2'-fucosyllactose, and belongs to the technical field of synthetic biology and microbial metabolism engineering. According to the invention, glycerol is taken as a carbon source, lactose and L-fucose are taken as substrates, and self-assembled oligopeptide-mediated pathway key enzymes Fkp and FutC are introduced to assemble and combine into an enzyme compound, so that the loss of metabolic intermediate products is reduced, the production efficiency of the products is improved, and the production yield and yield of the products 2'-FL are improved. In addition, a series of genes related to substrate degradation and intermediate product shunting in escherichia coli are knocked out through a CRISPR/Cas9 gene editing system, and meanwhile cyclic regeneration of cofactors in a metabolic pathway is enhanced, so that the yield of 2'-FL is further increased. The obtained escherichia coli engineering strain can accumulate 30.5 g/L of 2'-FL after being fed for 64 hours in batches under the condition of a 3L fermentation tank, and the molar yield is 0.661 mol(2'-FL)/mol fucose and 0.495 mol(2'-FL)/mol lactose. The invention has important significance on industrial production of the 2'-FL.

The invention belongs to the technical field of biological metabolism, and provides a system for reproducing an in vivo reaction in vitro. The system comprises the following steps: opening a computer, and dispatching kinetic parameters of related in vivo metabolism stored in a database; carrying out an intracellular and extracellular comparative dry experiment on a minimal metabolic network system only containing a cofactor metabolic intermediate CI, an enzyme, a substrate and a product; carrying out an intracellular and extracellular comparative experiment on an unrestraint metabolic network system containing a non-cofactor metabolic intermediate NCI, the cofactor metabolic intermediate CI, the enzyme, the substrate and the product; obtaining the influence of the concentration level of CI on the steady state level of NCI at high, middle and low inhibition levels; and simulating a gene knock-in and knock-out experiment by adjusting the enzyme content in the reaction process to obtain the result that the enzyme content has influence on the NCI and the reaction rate and that the inhibition mechanism, the cofactor metabolic intermediate CI, the enzyme content and the non-cofactor metabolic intermediate NCI have influence on intracellular reactions, and then an extracellular metabolic reaction system is obtained. The system provided by the invention makes up the blank of the industry.

Non-naturally occurring microbial organisms and related methods, processes and materials are for microbial organisms that include a genetic modification which enhances production of 3-hydroxybutanal or a downstream product of 3-hydroxybutanal such as 1,3-butanediol from endogenous central metabolic intermediates such as acetyl CoA or pyruvate which are converted to acetaldehyde. Two molecules of acetaldehyde are condensed to form the 3-hydroxybutanal using an aldolase capable of accepting acetaldehyde as both the acceptor and donor in an aldol condensation. The aldolase may be a deoxyribose phosphate aldolase type enzyme, and is typically introduced into the organisms. Energetically favorable pathways produce 3-hydroxybutanal or downstream products thereof.

The invention discloses application of fructose-1, 6-diphosphate in improving the anti-hypoxia ability of the body. The invention discloses application of fructose-1, 6-diphosphate in preparing products for improving the anti-low oxygen or anti-hypoxia ability of animals. Fructose-1, 6-diphosphate serves as a human body metabolic intermediate, exogenous supplementation of fructose-1, 6-diphosphate can improve the body's resistance to plateau hypoxia, and improve the athletic ability and anti-fatigue ability of the body in a plateau hypoxia environment.

The invention discloses a bio-energy active material and application thereof, and particularly discloses the bio-energy active material which is a biodegradable polymer. A degradation product of the bio-energy active material is a metabolic intermediate product in a tricarboxylic acid cycle and/or a glycolytic pathway, or a polymer monomer capable of being converted into the metabolic intermediate product in the tricarboxylic acid cycle and/or the glycolytic pathway, or a polymer monomer capable of being converted into acetyl coenzyme A. The degradation product of the bio-energy active material provides biological energy for tissue cells through the tricarboxylic acid metabolic cycle or the glycolysis pathway, so that the problem that a traditional biodegradable material cannot continuously improve the stability of ATP in cells and the activity of related biomass is solved; and the bio-energy active material has a wide application prospect in the field of bone tissue regeneration, especially in the aspect of large-segment bone defect repair.

The invention provides coenzyme self-sufficient Escherichia coli, a construction method of the coenzyme self-sufficient Escherichia coli and application of the coenzyme self-sufficient Escherichia coli in synthesis of L-glufosinate-ammonium. According to the invention, NADH kinase and a key enzyme of a coenzyme synthetic pathway are expressed in Escherichia coli, an enzyme for decomposing the coenzyme is knocked out, and in a cell culture process, by adding a combined metabolic intermediate, a concentration of intracellular NADP (H) is increased by at least 50%, and the catalytic activity of glutamate dehydrogenase is increased by 2 times. In a process of asymmetric reductive amination of 2-carbonyl-4-(hydroxymethylphosphinyl)-butyric acid, the NADH kinase continues to convert intracellular NAD (H) into the NADP (H), the lowering of the activity of the glutamate dehydrogenase caused by a too short half-life period of the NADP (H) is slowed down, an asymmetric reductive amination reaction process is shortened by at least 5h, and the space time yield of the reaction is remarkably increased.

A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan; and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drug reaction, thereby reducing the adverse drug reaction cased by the administration of irinotecan.